Schizophrenia News and Research

Latest Schizophrenia News and Research

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

18 Nov 2009

Review of the results of Phase 2b clinical trial on PASCAL announced

ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.

18 Nov 2009

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

New research provides valuable international profile of mental health disorder

An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries.

17 Nov 2009

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Study finds striking similarities in people with schizophrenia across 37 different countries

16 Nov 2009

Study confirms that people with severe mental disorders more at risk of dying from heart disease

A large new study confirms that people with severe mental disorders — such as schizophrenia or other psychotic disorders — are 25 percent to 40 percent more prone to die from heart disease than people without mental illness are.

13 Nov 2009

PKCI/HINT1 gene associated with mood regulation

Removing the PKCI/HINT1 gene from mice has an anti-depressant-like and anxiolytic-like effect. Researchers writing in the open access journal BMC Neuroscience applied a battery of behavioral tests to the PKCI/HINT1 knockout animals, concluding that the deleted gene may have an important role in mood regulation.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics, Inc. today reported results of operations and provided a general business update for the third quarter ended September 30, 2009.

12 Nov 2009

Results from an analysis emphasizes the financial burden of SMI on the criminal justice and HHS systems

Results from a large, retrospective analysis of inmates with a serious mental illness (SMI) underscores the financial burden of mental illness on the criminal justice and health and human services (HHS) systems, and may provide useful information to policy makers.

12 Nov 2009

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Academic Health Center scientists, physicians, and research centers have attracted 128 grants totaling nearly $35 million in federal stimulus money (as of Nov. 10) since the American Recovery and Reinvestment Act was approved in February 2009. This will result in a total economic impact of more than $105 million; according to the National Institutes of Health, $1 of research funding multiplies to more than $2 of goods and services in the economy.

11 Nov 2009

Re-classification of cannabis will have minimal impact on incidence of psychosis says study

The research follows last year’s decision by the UK government to reclassify the drug from class C to class B, partly out of concerns that cannabis, especially the more potent varieties, may increase the risk of schizophrenia in young people. However, the evidence for the relationship between cannabis and schizophrenia or psychosis remains controversial.

5 Nov 2009

Health care jobs plentiful but tough to get

While health care jobs are plentiful, "getting one is hard work," The Associated Press/The News-Sentinel reports. "Many people who have lost jobs to the recession may find a cure for unemployment in the health care field," and the demand for nurses, specialists and technicians is strong

4 Nov 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

NARSAD to present Productive Lives Award to Randy Lewis

Randy Lewis, the SVP of supply chain and logistics for Walgreens, the nation’s largest drugstore chain, will receive the first ever Productive Lives Award from NARSAD tonight at its 22nd annual New York Awards Dinner at the Pierre Hotel.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

BIMR wins a GO grant from the National Institute of Mental Health

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Review of the results of Phase 2b clinical trial on PASCAL announced

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

New research provides valuable international profile of mental health disorder

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Study finds striking similarities in people with schizophrenia across 37 different countries

Study confirms that people with severe mental disorders more at risk of dying from heart disease

PKCI/HINT1 gene associated with mood regulation

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

ARYx Therapeutics announces operating results for the third quarter of 2009

Results from an analysis emphasizes the financial burden of SMI on the criminal justice and HHS systems

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Re-classification of cannabis will have minimal impact on incidence of psychosis says study

Health care jobs plentiful but tough to get

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

NARSAD to present Productive Lives Award to Randy Lewis

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Schizophrenia News and Research

Latest Schizophrenia News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in